Lack of association between ACE I/D and AGTR1 A1166C gene polymorphisms and preeclampsia in Turkish pregnant women of Trakya region

Nevra Alkanli¹, Tammam Sipahi¹,*, Tulay Okman Kilic², Seralp Sener¹

¹Department of Biophysics, Faculty of Medicine, Trakya University, Edirne, Turkey
²Department of Obstetrics and Gynecology, Faculty of Medicine, Trakya University, Edirne, Turkey

Email address: tammam@trakya.edu.tr (T. Sipahi)

To cite this article:

Abstract: The aim of this study was to investigate the distribution of Angiotensin Converting Enzyme Insertion/Deletion (ACE I/D) and the distribution of Angiotensin II Type 1 Receptor A1166C (AGTR1 A1166C) gene polymorphisms in preeclamptic pregnant women comparing to control pregnant women in Turkish subjects of Trakya Region. We aimed to determine whether these polymorphisms are genetic risk factor for preeclampsia. The study included 75 preeclamptic pregnant women and 75 control pregnant women, which were categorized according to The World Health Organization Detecting Pre-eclampsia: A Practical Guide. The ACE I/D gene polymorphism was investigated using Polymerase Chain Reaction (PCR) method. The AGTR1 A1166C gene polymorphism was identified using PCR and followed by Restriction Fragment Length Polymorphism (RFLP) methods. The ACE I/D genotype distribution in preeclamptic pregnant women DD=36.0%, ID=44.0% and II=20.0% did not significantly differ from those in control pregnant women DD=38.7%, ID=50.7% and II=10.6% (P=0.279). The AGTR1 A1166C genotype distribution in preeclamptic pregnant women AA=57.3%, AC=33.4% and CC=9.3% also did not significantly differ from those in control pregnant women AA=70.7, AC=24.0% and CC=5.3% (P=0.223). This case-control study show that ACE I/D and AGTR1 A1166C gene polymorphisms are not genetic risk factors for preeclampsia in this population in Turkish pregnant women of Trakya Region.

Keywords: Preeclampsia, ACE I/D Gene Polymorphism, AGTR1 A1166C Gene Polymorphism, PCR, RFLP

1. Introduction

Preeclampsia (PE), characterized by the development of hypertension and proteinuria after 20 weeks of gestation, is a common and serious disease that complicates in 5% to 8% of human pregnancies and remains a leading cause of maternal mortality and fetal morbidity (1). Abnormalities in the maternal immune system and lack of gestational immune tolerance appear to play major roles in PE. Furthermore, several pathophysiological mechanisms have been implicated in the development of PE include endothelial dysfunction, inflammatory pathway, oxidative stress, activation of thrombosis and the compensatory and delicate changes of Renin Angiotensin Aldosterone System (RAAS) during normal pregnancy (1,2).

The Pathogenesis of PE remains obscure, but it has been considered to be a multifactorial and multisystemic disorder, especially with a genetic predisposition (3). Several features of the RAAS in PE differ from that in normal pregnant state. RAAS could be the foundation for the genetics of PE and the various gene polymorphisms of RAAS seem most likely related to the development of PE disease (1-3).

RAAS components play a central role in the regulation of blood pressure, sodium metabolism and renal hemodynamics. RAAS comprises of the Angiotensinogen (AGT), Renin, Angiotensin I (ANG I), Angiotensin Converting Enzyme (ACE), Angiotensin II (ANG II), and Angiotensin II Coupled Receptors which are members of the G protein-coupled receptor superfamily (4, 5). Also agonistic antibodies against AGTR1 have been identified in pregnant women with PE (6).

ACE, a peptidyl carbboxypeptidase is an important
protease enzyme of the RAAS that regulates blood pressure by catalyzing the conversion of ANG I into ANG II (7). ANG II is a potent vasoconstrictive molecule that plays a key role in modulating vascular tone. ANG II exerts its effects by binding to ANG II Coupled Receptors. Most of the known effects of ANG II can be attributed to the AGTR1 (4). AGTR1 mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system which implicated in PE, followed by vasoconstriction, hypertrophy, or catecholamine liberation at sympathetic nerve endings (4, 5).

The ACE gene maps on chromosome 17 (17q23.3), spans 21 kb, and comprises of 26 exons and 25 introns. The ACE I/D gene polymorphism is due to the insertion or deletion of an alu short interspersed sequence, various base sequences dispersed in human, located on intron 16 (7).

The human AGTR1 gene is located on chromosome 3 (3q21-q25) and comprises of 5 exons and 4 introns. The AGTR1 A1166C gene polymorphism has been described in which there is either an Adenine (A) or a Cytosine (C) base in position 1166 in the 3’ untranslated region of the gene (8).

Several studies of RAAS components, responsible for high blood pressure, showed that ACE I/D and AGTR1 A1166C gene polymorphisms were associated with increased risk for hypertension (9, 10). On the other hand, there was no relationship between ACE I/D and/or AGTR1 A1166C gene polymorphisms and hypertension in the other studies (11, 12). In PE, evidence is accumulating that ACE I/D and AGTR1 A1166C gene polymorphisms are also associated with increased risk of PE disease (13, 14). In addition, various genetic and environmental risk factors have been considered to contribute in increasing the effects of these polymorphisms such as geographic, socioeconomic, and racial features. This prompted us initiating to examine the relationship between development of PE disease and gene polymorphisms of ACE and AGTR1 in Turkish pregnant women of Trakya Region.

2. Materials and Methods

The study included a total of 150 Turkish women containing 75 preeclamptic pregnant women which were categorized according to The World Health Organization Detecting Pre-eclampsia: A Practical Guide and 75 control pregnant women. The definition used for PE is based on high blood pressure and proteinuria. High blood pressure: Two separate readings taken at least six hours apart of 140 mmHg or more in systolic and/or 90 mmHg or more in diastolic blood pressure. Proteinuria: 300 mg of protein in a 24 hour urine sample after 20 weeks of pregnancy. The control pregnant women group among eligible subjects who were not affected by PE in the pregnancy progressing to >20 weeks gestation. Both of the preeclamptic and the control pregnant women were from Edirne or its surrounding areas with comparable socioeconomic cultural backgrounds. All participants gave informed consent that was approved by the local ethics committee.

2.1. DNA Isolation

DNA was isolated from peripheral blood, containing EDTA as an anticoagulant, by cZNA blood DNA kits (BOGA, Istanbul, Turkey). DNA purity and quality were assessed by absorbance values in spectrophotometer. The ratio of Optical Density (OD) at 260 nm to OD at 280 nm was found about 1.8 for all samples. DNA bands were observed by 0.8 agarose gel electrophoresis (Figure 1).

![Figure 1. Ethidium bromide-stained 0.8% agarose gel of representative DNA samples.](image)

2.2. Genotyping of ACE I/D Gene Polymorphism

To determine the ACE I/D gene polymorphism of the preeclamptic and the control groups, a genomic DNA fragments on intron 16 of the ACE gene was amplified by PCR in a 15µl PCR reaction mixture containing 100 ng of DNA, dNTP (0.2 mM of each), upstream and downstream primers (300 pmol), 1X Taq Buffer (75 mM Tris-HCl pH 8.8, 20 mM (NH4)2SO4, 0.01% Tween 20), 2.5 mM MgCl2 and 0.75 U of Taq DNA polymerase (Fermentas Life Sciences).

Upstream primer was: 5’-CTGGAGACCCACTCCCATCCTTCTTCT-3’

Downstream primer was: 5’-GATGTGGCCATCATTGTCAGAT-3’

Amplification were performed with 5 minute of denaturation at 94 C, followed by 30 cycles with denaturation for 1 minute at 94 C, annealing for 1 minute at 58 C, and extension for 1 minute at 72 C, followed by 7 minute of extension at 72 C (15,16). The PCR products of two alleles of 490 bp and 190 bp were electrophoresed in 2% agarose gels, and visualized under ultraviolet (UV) light by ethidium bromide straining (Figure 2).

![Figure 2. Ethidium bromide-stained 2% agarose gel of representative PCR products of ACE I/D gene polymorphism shows the DD genotype (190 bp, lane 2, 5, 7 and 8), the ID genotype (190 bp and 490 bp, lane 3, 4, 6, 9 and 10) and the II genotype (490 bp, lane 1), lane 50 bp is a size marker (GeneRuler 50 bp DNA Ladder), and lane (-) is a negatif control.](image)
2.3. Genotyping of AGTR1 A1166C Gene Polymorphism

AGTR1 A1166C gene polymorphism was identified with PCR and followed by RFLP with the restriction enzyme HaeIII. 25 μl PCR reaction mixture containing 200 ng, dNTP (0.2 mM of each), 500 pmol of each primer, 1×Taq Buffer (75 mM Tris-HCl pH 8.8, 20 mM (NH₄)₂SO₄, 0.01% Tween 20), 1.5 mM MgCl₂ and 1.25 U of Taq DNA polymerase.

Upstream primer was: 5’-CGCACCTCATTCAACAAATGGGC-3’
Downstream primer was: 5’-CAGGACAAAGCAGGCTACGAG-3’

Amplification were performed with denaturation for 5 minute at 94 °C, followed by 35 cycles with denaturation for 1 minute at 94 °C, annealing for 1 minute at 55 °C, and extension for 1 minute at 72 °C, followed by 7 minute of extension at 72 °C (16). The PCR products were electrophoresed in 2% agarose gels, and visualized under UV light by ethidium bromide staining. 5 µl of PCR restriction digest products were visualized by UV light after cutting site for HaeIII, so that the 255 bp PCR product was not cleaved into 231 bp and 24 bp fragments (16). The restriction digest products were visualized by UV light after ethidium bromide staining on a 2.5% agarose gel and ethidium bromide staining (Figure 3).

Figure 3. Ethidium bromide-stained 2.5% agarose gel of representative PCR digested products of AGTR1 A1166C gene polymorphism shows the AA genotype (255 bp, lane 3, 5, 6, 8, 9, and 11), the AC genotype (255 bp, 231 bp and 24 bp (not detectable in agarose gel) lane 1, 4, 7, and 10) and the CC genotype (231 bp and 24 bp lane 2); lane 50 bp is a size marker.

2.4. Statistical Analyses

All statistical analyses were performed with the SPSS 15.0 software and STATA program, version 8. Genotype distribution of ACE I/D and AGTR1 A1166C of preeclamptic pregnant patients and control pregnant groups were evaluated by Chi-square test (χ² test). Maternal age, gestational age, number of pregnancy, Body Mass Index (BMI), Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were examined by χ² test or an independent student’s t-test. The all values are represented as mean ± Standard Deviation (SD). Significance was defined as p<0.05.

3. Results

The maternal age, the gestational age, the number of pregnancy and other characteristics such as BMI, SBP and DBP of 75 pregnant women with PE and 75 pregnant controls are presented in Table 1. No significant differences were detected between preeclamptic pregnant and control pregnant groups for the maternal age, the gestational age and the number of pregnancy (p>0.05). On the other hand, BMI, SBP and DBP as expected were significantly differed between the case-control groups (p<0.05).

Table 1. The clinical characterisitics of preeclamptic and control groups.

<table>
<thead>
<tr>
<th></th>
<th>Preeclamptic Group (n=75)</th>
<th>Control Group (n=75)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal Age (Years)</td>
<td>27.87 ±6.44</td>
<td>27.39 ±6.87</td>
<td>NS</td>
</tr>
<tr>
<td>Gestational Age (Weeks)</td>
<td>36.5 ±3.6</td>
<td>34.5 ±4.0</td>
<td>NS</td>
</tr>
<tr>
<td>Number of Pregnancy</td>
<td>1.56±0.93</td>
<td>1.72±1.20</td>
<td>NS</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.99 ±5.59</td>
<td>23.83 ±3.38</td>
<td>0.001</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>156.67 ±4.08</td>
<td>114.80 ±5.03</td>
<td>0.001</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>100.80±11.83</td>
<td>73.33±4.75</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Genotype frequencies for the ACE I/D gene polymorphism is presented in Table 2. The overall frequencies of the genotypes DD, ID and II in preeclamptic pregnant group were 27 (36.0%), 33 (44.0%) and 15 (20.0%) were not significantly differ from genotype frequencies in control pregnant group 29 (38.7%), 38 (50.7%) and 8 (10.6%) (p=0.279).

Table 2. Genotype frequencies for the ACE gene of PE and control groups.

<table>
<thead>
<tr>
<th>GENOTYPE</th>
<th>GROUP</th>
<th>PATIENT</th>
<th>CONTROL</th>
<th>TOTAL</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DD</td>
<td></td>
<td>27 (%36.0)</td>
<td>29 (%38.7)</td>
<td>56 (%37.3)</td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td></td>
<td>33 (%44.0)</td>
<td>38 (%50.7)</td>
<td>71 (%47.3)</td>
<td>0.279</td>
</tr>
<tr>
<td>II</td>
<td></td>
<td>15 (%20.0)</td>
<td>8 (%10.6)</td>
<td>23 (%15.3)</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td>75 (%100.0)</td>
<td>75 (%100.0)</td>
<td>150 (%100.0)</td>
<td></td>
</tr>
</tbody>
</table>

DD; Deletion-Deletion, ID; Insertion-Deletion, II; Insertion-Insertion
Statistical analysis was performed by using Chi-square test

Genotype frequencies for the AGTR1 A1166C gene polymorphism is presented in Table 3. AGTR1 A1166C genotypes AA, AC and CC in preeclamptic pregnant group were 43 (57.3%), 25 (33.4%) and 7 (9.3%) respectively did not differ from genotype distribution in control pregnant group 53 (70.7%), 18 (24.0%) and 4 (5.3%) (p=0.223).

Our findings, in this case-control study populating,
indicate that the ACE I/D and the AGTR1 A1166C gene polymorphisms were not genetic risk factors for PE in this population in Turkish pregnant women of Trakya Region.

Table 3. Genotype frequencies for the AT1R (A1166C) polymorphism of PE and control groups.

<table>
<thead>
<tr>
<th>GENOTYPE</th>
<th>PATIENT</th>
<th>CONTROL</th>
<th>TOTAL</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>43 (%57.5)</td>
<td>53 (%70.7)</td>
<td>96 (%64.0)</td>
<td></td>
</tr>
<tr>
<td>AC</td>
<td>25 (%33.4)</td>
<td>18 (%24.0)</td>
<td>43 (%28.7)</td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>7 (%9.3)</td>
<td>4 (%5.3)</td>
<td>11 (%7.3)</td>
<td>0.223</td>
</tr>
<tr>
<td>TOTAL</td>
<td>75 (%100.0)</td>
<td>75 (%100.0)</td>
<td>150 (%100.0)</td>
<td></td>
</tr>
</tbody>
</table>

AA; Adenine-Adenine, AC; Adenine-Cytosine, CC; Cytosine-Cytosine
Statistical analysis was performed by using Chi-square test

4. Discussion

PE caused by secretion of inflammatory mediators from the placenta which finally affects the vascular endothelium. ANG II which has a critical role in increasing the blood pressure, has a serious role in producing an inflammatory response that appears to be involved in the pathogenesis of pregnancy (2). Elevation of the blood pressure is the most visible sign of the disease. Several studies identified various candidate genes involved in high blood pressure of pregnancy. Special attention on genes of the RAAS as AGT, ACE and AGTR1 which play key roles in blood pressure regulation and electrolyte balance (2,9,10,17).

Many researchers investigated the relationship of PE and the common gene polymorphisms of the RAAS. I/D gene polymorphism of intron 16 of the ACE gene on chromosome 17 and A1166C gene polymorphism in the 3’-untranslated region at nucleotide 1166 of the AGTR1 gene on chromosome 3 (13,14) are the most important gene polymorphisms.

The frequency of the ACE I/D and the AGTR1 A1166C genotypes and their possible associations with the risk of PE have been investigated in different populations. Studies of the association of the ACE I/D and the AGTR1 A1166C gene polymorphisms with PE reported both positive (13, 14) and negative (13, 18) results. In Korean and Colombian populations, the ACE I/D polymorphism (19, 20) was not associated with the pathogenesis of PE. Also, in Greek and South African Black women (21, 22) neither ACE I/D nor AGTR1 A1166C variants were independently and directly associated with the risk of PE. In contrast, there are studies indicating that ACE I/D gene polymorphism might have a role in complications of pregnancy, including PE. In studies from South Eastern Iran (13) and Turkey (23) the presence of D allele of ACE was associated with increased risk of PE. In Northern India (24) of ACE I/D gene polymorphism appears to predispose to severe PE but not nonsevere PE. The study by Uma et al. suggested an association between the DD genotype of the ACE gene and early-onset but not later-onset PE (25). Furthermore, in a meta-analysis by Chen et al. (26) including 30 case-control studies the DD genotype of ACE was significantly associated with increased risk of pregnancy hypertensive disorders, especially among Asian and Caucasians. In Korean women the frequency of the DD genotype in patients with PE was about 2.5 times higher compared to general population and normotensive women during pregnancy (27). However, there were other studies showing that PE disease could be associated with I allele of the ACE gene (28).

Associations between AGTR1 A1166C gene polymorphism and PE have been investigated in the ethnicity meta-analysis, the results in Asians suggested that the C allele and the AC/CC genotypes were associated with risk of pregnancy hypertensive disorders (14). However, many investigators found no association between the AGTR1 A1166C gene polymorphism and PE, neither in the Iran, Afro-Caribbean or Caucasian nor in Asian women populations (13, 29). Similar findings have been reported previously in meta-analysis findings which did not support AGTR1 A1166C as a susceptibility locus for development of PE disease (30).

In our study, ACE I/D genotype distribution DD, ID and II in preeclamptic pregnant group were 27 (36.0%), 33 (44.0%) and 15 (20.0%) did not differ from control pregnant group 29 (38.7%), 38 (50.7%) and 8 (10.6%). For AT1R (A1166C) genotype distribution AA, AC and CC in preeclamptic pregnant group 43 (57.3%), 25 (33.4%) and 7 (9.3%) did not also differ from control pregnant group 53 (70.7%), 18 (24.0%) and 4 (5.3%). Our results show that ACE I/D and AT1R (A1166C) gene polymorphisms were not genetic risk factors for PE in this population of Turkish pregnant women of Trakya region. However, in the preeclamptic pregnant group compared to control pregnant group there was a higher proportion of the AGTR1 CC genotype.

References

patients stimulate increased intracellular Ca\(^{2+}\) mobilization through angiotensin receptor activation. Circulation. 2004; 110 (12): 1612-1619.


